While a majority of mCRPC remain AR-driven during tumor progression, it has now been shown that a subset of mPC is able to adapt under the therapeutic pressure of hormone therapy by becoming less AR dependent (and thus losing luminal cell markers such as PSA) and developing lineage plasticity. This evidence concerns the gene AR and neoplasm.